Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 5/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | GLA | P06280 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31015931 | 0.88 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL8142110 | 0.88 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL8141564 | 0.85 | KDM4E (0.68) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL19024706 | 0.85 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL10481468 | 0.84 | LMNA (0.48) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL17149279 | 0.84 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL16096207 | 0.84 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL31519888 | 0.82 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL2063949 | 0.82 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL19283497 | 0.82 | LMNA (0.47) | KDM4EALDH1A1HPGDHSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116390-A1 | PYRIMIDINE-2(1H)-ONE-FUSED BICYCLIC COMPOUND HAVING MAT2A INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20200161564-A1 | ORGANIC COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-05-21 | — | — | US | disclosed |
| WO-2017144341-A1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144341-A1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-08-31 | — | — | WO | disclosed |
| US-8148384-B2 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; ischemia reperfusion injury, inflammatory disease, retroviral infections, ischemia reperfusion injury, myocardial infarction | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2008082840-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082839-A2 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | PIM1, PIM2, PIM3 | KDM4E 820/4885ALDH1A1 984/4885HPGD 1027/4885 |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | KDM4E 1232/4885ALDH1A1 1668/4885HPGD 1749/4885 |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | KDM4E 1232/4885ALDH1A1 1668/4885HPGD 1749/4885 |
| US-20200161564-A1 | ORGANIC COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | OXER1, OR10J3, OCIAD1 | KDM4E 4066/4885ALDH1A1 91/4885HPGD 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.